BC
ALXN

Brinker Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Brinker Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$1.24M Buy
11,037
+701
+7% +$74.4K 0.04% 444
2020
Q1 		$928K Buy
10,336
+3,096
+43% +$304K 0.04% 445
2019
Q4 		$783K Sell
7,240
-1,611
-18% -$172K 0.02% 586
2019
Q3 		$867K Buy
8,851
+684
+8% +$77.1K 0.03% 535
2019
Q2 		$1.07M Sell
8,167
-1,909
-19% -$246K 0.04% 445
2019
Q1 		$1.36M Buy
10,076
+3,364
+50% +$418K 0.05% 370
2018
Q4 		$653K Sell
6,712
-870
-11% -$103K 0.03% 527
2018
Q3 		$1.05M Buy
7,582
+1,804
+31% +$226K 0.04% 484
2018
Q2 		$717K Buy
5,778
+93
+2% +$10.9K 0.03% 599
2018
Q1 		$634K Buy
5,685
+962
+20% +$115K 0.02% 630
2017
Q4 		$565K Buy
4,723
+159
+3% +$19.4K 0.02% 649
2017
Q3 		$640K Buy
+4,564
New +$620K 0.03% 580
2017
Q2 		– Sell
-3,493
Closed -$423K – 921
2017
Q1 		$423K Sell
3,493
-560
-14% -$72.2K 0.02% 649
2016
Q4 		$496K Buy
+4,053
New +$496K 0.03% 456

Other funds holding ALXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brinker Capital's ALXN Position: Q2 2020 in Review

Brinker Capital increased its Alexion Pharmaceuticals (ALXN) stake by 6.8% in Q2 2020, buying an estimated $74.4K and bringing the position to 11,037 shares worth $1.24M. The position accounts for 0.04% of the portfolio, ranked #444.

Brinker Capital first reported a position in ALXN in Q4 2016 and has held it in 14 quarters since. The position peaked at $1.36M in Q1 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Brinker Capital held 11,037 shares of Alexion Pharmaceuticals worth $1.24M as of Q2 2020.
  • Brinker Capital bought 701 Alexion Pharmaceuticals shares in Q2 2020, an estimated $74.4K.
  • Alexion Pharmaceuticals made up 0.04% of Brinker Capital's portfolio in Q2 2020, its #444 holding.
  • Brinker Capital first reported a position in Alexion Pharmaceuticals in Q4 2016 and has held it in 14 quarters since.
  • Brinker Capital's Alexion Pharmaceuticals position peaked at $1.36M in Q1 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.